Imbed Biosciences has been quietly doing what the best companies do. No noise, no cosplay entrepreneurship, just real science, real clinicians, real scars earned in the field. Founded in 2010 out of the University of Wisconsin Madison by a crew of physicians and scientists who actually touch wounds for a living, Imbed did not chase hype. It chased outcomes. That matters in a $22B wound care market where 8M Americans are living with chronic wounds and the system spends $148B a year trying to clean up what half baked solutions leave behind.
The latest chapter lands with a strategic investment from BioLab Holdings, announced February 3, 2026. The amount stays private, which is usually a good tell. BioLab Holdings, led by President, CEO and Co-Founder Jaime Leija, knows membranes, protection, and what clinicians will actually use when nobody is watching. This is not financial tourism. This is product people betting on product people, and that alignment shows up long before the first sales deck hits a conference room.
Imbed Biosciences is led by CEO Terry Bromley, a veteran who has spent 30 years inside medical device and wound care markets, long enough to know where innovation survives and where it dies of committee. Founder and Chief Scientific and Quality Officer Ankit Agarwal, PhD built the core SAM synthetic antimicrobial matrix technology during postdoctoral research, which explains why it behaves like science instead of marketing. Chief Medical Officer Michael J. Schurr, MD brings the surgeon’s eye, because products that never leave the lab tend to fail quietly and expensively.
The Microlyte platform tells the story. Fully synthetic. Antimicrobial. Bioresorbable. No human or animal tissue. Over 100,000 unit applications already used in real wounds, not hypotheticals. FDA 510(k) clearances, including Microlyte Ag and the Ag Lidocaine version that integrates pain management without compromising antimicrobial performance. That combination alone should make clinicians lean forward, because comfort and infection control rarely play this nicely together.
BioLab Holdings adds reach, distribution muscle, and shared obsession with wound protection. Imbed brings a matrix that actually embeds itself into workflows instead of fighting them. The funding will expand U.S. market reach, especially in physician office settings, and accelerate the SAM platform into next generation matrices that do more while asking less from the clinician.
